Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study

BACKGROUND: The tyrosine kinase inhibitor pazopanib is used for treatment of sarcoma. Recent studies have suggested that the use of pazopanib may lead to the development of pneumothorax, an unexpected adverse effect in patients with sarcoma metastatic to the chest. METHODS: We conducted a retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabath, Bruce, Muhammad, Hasan A, Balagani, Amulya, Ost, David E, Vakil, Erik, Ahmed, Tahreem, Vial, Macarena R, Grosu, Horiana B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167904/
https://www.ncbi.nlm.nih.gov/pubmed/30285733
http://dx.doi.org/10.1186/s12885-018-4858-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167904/
https://www.ncbi.nlm.nih.gov/pubmed/30285733
http://dx.doi.org/10.1186/s12885-018-4858-8

Ejemplares similares